Search 

Oncimmune, a global leader in immunodiagnostics and (auto) antibody biomarker profiling & discovery in immuno-oncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the company provides insights to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy. Oncimmune is headquartered in the UK with operations in Germany and USA.

Oppilotech is a science-driven company founded by a group of friends with the shared ambition to improve human health. The founding team: Ajay, John, Cora, Tony and Keith; have many years of experience working in Pharma, Biotech and academia spanning fundamental R&D, drug discovery, business development, investment and IP management.

Our unique blend of skills combined with a love of science have made Oppilotech an exciting, dynamic, flexible and collaborative company.

Spun out of hVIVO plc (formerly Open Orphan plc) in 2021, we have access to over 20 years knowledge, expertise, and clinical data from hVIVO.We are led by a team with proven capabilities in identifying, acquiring, and accelerating assets through development to commercialisation.sing innovative technologies, we are developing a range of products to address diseases with a high unmet medical need.

We aim to rapidly generate early human efficacy data and then partner / out-licence our products to pharma & biotech companies for further development.

Better valuation of development and software investments can give you a tax-advantage - Bespoke developments don't always deliver on budget and schedule. Revaluation in line with market and utility values can realize immediate and long terms value.

Research Donors collects, processes and delivers human blood biospecimens that meet the most demanding research requirements. With a diverse community of  over 2500 donors, we can meet any donor specification as required by your project. Fresh HLA typed human leukopaks, PBMCs, whole blood and blood derivatives, all consented for commercial and genetic research, can be delivered within 24 hours of collection across Europe.

Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges. 

RoslinCT, as one of the first in the world to produce clinical-grade human pluripotent stem cells, has a strong focus on science and innovation. In collaboration with our partners, RoslinCT developed, from early process development through commercialization, the First CRISPR-Edited Cell Therapy Product for a major inherited disorder (high volume).